Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunosuppressive therapy.

A Jain1, A Khanna, E P Molmenti

  • 1Thomas E. Starzl Transplantation Institute, Pittsburgh, Pennsylvania, USA.

The Surgical Clinics of North America
|March 12, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2008
Same author

Genetic polymorphism of type 1 intermediate filament wool keratin gene in native Indian sheep breeds.

Biochemical genetics·2008
Same author

Toxicity of Certain Penta-Coordinated Organotin(IV) and Tetra-Coordinated Tin(II) Complexes of Heterocyclic beta-Diketones Against the Larvae of Aedes Aegypti (Liston).

Metal-based drugs·2008
Same author

Time resolved fluorescence spectroscopy of Eu(III) complexation with alpha-hydroxy isobutyric acid.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2008
Same author

Design and development of a mucoadhesive buccal film bearing progesterone.

Die Pharmazie·2008
Same author

Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension.

Clinical drug investigation·2008

New immunosuppressive drugs offer improved rejection management but not survival benefits over older agents. Future goals include combination therapies and tolerance induction to minimize drug toxicity in organ transplantation.

Area of Science:

  • Immunosuppression
  • Transplantation Medicine
  • Pharmacology

Background:

  • Several novel immunosuppressive medications have emerged in the last decade.
  • These newer agents aim to improve outcomes in organ transplantation.
  • Cyclosporine A (CsA) and tacrolimus remain benchmarks for immunosuppression.

Purpose of the Study:

  • To evaluate the impact of new immunosuppressive agents on organ transplantation.
  • To compare the efficacy and toxicity profiles of newer versus established immunosuppressants.
  • To explore future strategies for optimizing immunosuppression and achieving graft tolerance.

Main Methods:

  • Review of recent advancements in immunosuppressive drug development.
  • Comparative analysis of clinical outcomes associated with different immunosuppressive regimens.

Related Experiment Videos

  • Assessment of side effect profiles and toxicity mitigation strategies.

    • Main Results:

    • Newer immunosuppressants have not demonstrated superior patient or graft survival rates compared to CsA or tacrolimus.
    • These agents effectively reduce the incidence and severity of rejection episodes.
    • They enable decreased steroid use and lower doses of CsA/tacrolimus, thereby minimizing toxicity.

    Conclusions:

    • New immunosuppressive drugs provide valuable therapeutic options for managing rejection and reducing toxicity.
    • Personalized selection of immunosuppressants based on efficacy and toxicity is crucial.
    • Future research should focus on combination therapies and strategies for inducing donor-specific tolerance to eliminate drug dependency.